Roth Capital Initiates Equity Research Analyst Coverage on Aeolus
October 05 2011 - 11:28AM
Marketwired
Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) (PINKSHEETS: AOLS), a
biotechnology company that is leveraging up to $140M of government
funding in developing a platform of a new class of broad-spectrum,
catalytic-antioxidant compounds as medical countermeasures against
radiation exposure to develop them in oncology indications, today
announced that Roth Capital Partners, LLC initiated equity research
coverage on the Company with a "Buy" recommendation and a 12-month
price target of $3.00 per share. The new report, issued on October
5, 2011 was authored by Joseph Pantginis Ph.D., Senior Research
Analyst.
To request a copy of the report, please contact Joseph
Pantginis. His contact information can be found at
http://www.aeoluspharma.com/?page_id=367.
Neither Aeolus Pharmaceuticals, Inc., nor any of its affiliates,
endorse, confirm or adopt the contents of the Roth Capital equity
research report nor accept any responsibility for its accuracy,
which is the sole responsibility of its author. Aeolus undertakes
no obligation to revise or update this Report to reflect events or
circumstances after its issuance or otherwise. The reader should
review all disclaimers contained in this Report. Aeolus is subject
to significant risks, and a discussion of such risks can be found
by reviewing Aeolus' SEC filings including Annual and Quarterly
Reports as filed on Form 10-K and Form 10-Q respectively.
About AEOL 10150
AEOL 10150 is a broad-spectrum, catalytic-antioxidant
specifically designed to neutralize reactive oxygen and nitrogen
species. The neutralization of these species reduces oxidative
stress, inflammation, and subsequent tissue damage-signaling
cascades resulting from radiation exposure.
AEOL 10150 has already performed well in preclinical studies,
was well-tolerated in two human clinical trials, and has
demonstrated statistically significant survival efficacy in an
acute radiation-induced lung injury model. The Company believes it
could have a profound beneficial impact on people who have been
exposed, or are about to be exposed, to high-doses of radiation,
whether from cancer therapy or a nuclear event.
About Aeolus Pharmaceuticals
Aeolus Pharmaceuticals is developing a platform of a new class
of broad-spectrum, catalytic-antioxidant compounds as medical
countermeasures against radiation exposure and in oncology
indications.
Its lead compound, AEOL 10150, is being developed for oncology
indications, where it is used in combination with radiation
therapy. It is also being developed, with funding by the US
Government, as a medical countermeasure against chemical and
radiological weapons, where its initial target indications are as a
protective agent against the effects of acute radiation syndrome
and delayed effects of acute radiation exposure. Aeolus' strategy
is to leverage the substantial investment in toxicology,
manufacturing, and preclinical and clinical studies made by US
Government agencies in AEOL 10150, including the contract with
BARDA valued, with options, at up to $118 million, to efficiently
develop the compound for use in oncology.
Forward-Looking Statements
The statements in this press release that are not purely
statements of historical fact are forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that may cause Aeolus' actual
results to be materially different from historical results or from
any results expressed or implied by such forward-looking
statements. Certain of these factors and others are more fully
described in Aeolus' filings with the Securities and Exchange
Commission, including, but not limited to, Aeolus' amended Annual
Report on Form 10-K/A for the year ended September 30, 2010.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date
hereof.
Add to Digg Bookmark with del.icio.us Add to Newsvine
Contact: Russell Skibsted (949) 481-9825
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aeolus Pharmaceuticals (CE) (USOTC:AOLS)
Historical Stock Chart
From Jul 2023 to Jul 2024